Search
Search
About
Log in
Join
Experiences with
Ropeginterferon alfa-2b
Posts
Communities
69 public posts
Filter results
Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)
No specific baseline characteristics among low-risk PV patients appear to be associated with long-term response to
ropeginterferon
alfa
-
2b
.
No specific baseline characteristics among low-risk PV patients appear to be associated with long-term response to
ropeginterferon
alfa
-
2b
.
Manouche
in
MPN Voice
5 months ago
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
Discussion; The results in our study demonstrate that the new dosing regimen of 250-350-500 µg of
ropeginterferon
alfa
-
2b
is well-tolerated and highly efficacious in patients suffering from PV.
Discussion; The results in our study demonstrate that the new dosing regimen of 250-350-500 µg of
ropeginterferon
alfa
-
2b
is well-tolerated and highly efficacious in patients suffering from PV.
Manouche
in
MPN Voice
22 days ago
Event-free survival in patients with polycythemia vera treated with Besremi versus best available treatment
This potential advantage should be considered when evaluating the individual risk-benefit relationship for
ropeginterferon
alfa
-
2b
treatment in patients with PV » https://www.nature.com/articles/s41375-023-02008-6
This potential advantage should be considered when evaluating the individual risk-benefit relationship for
ropeginterferon
alfa
-
2b
treatment in patients with PV » https://www.nature.com/articles/s41375-023-02008-6
Manouche
in
MPN Voice
9 months ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
BESREMi now recommended as a Preferred First-line Cytoreductive Therapy for PV in Updated NCCN Clinical Practice Guidelines in Oncology
« The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have recently been updated to include
ropeginterferon
alfa
-
2b
-njft, marketed as BESREMi®, as a preferred first-line cytoreductive therapy option for the treatment of adults with symptomatic, low-risk
« The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have recently been updated to include
ropeginterferon
alfa
-
2b
-njft, marketed as BESREMi®, as a preferred first-line cytoreductive therapy option for the treatment of adults with symptomatic, low-risk
Manouche
in
MPN Voice
3 months ago
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
Over a lifetime, the model showed that patients who received
ropeginterferon
alfa
-
2b
-njft had more years alive (0.4), and higher QALYs (0.4), and higher cost (141,783). What do the results mean?
Over a lifetime, the model showed that patients who received
ropeginterferon
alfa
-
2b
-njft had more years alive (0.4), and higher QALYs (0.4), and higher cost (141,783). What do the results mean?
Manouche
in
MPN Voice
9 months ago
Ropeginterferon Alfa-2b listed as Preferred Treatment in Polycythemia Vera
https://www.onclive.com/view/nccn-guidelines-list-
ropeginterferon
-
alfa
-
2b
-as-preferred-treatment-in-polycythemia-vera
https://www.onclive.com/view/nccn-guidelines-list-
ropeginterferon
-
alfa
-
2b
-as-preferred-treatment-in-polycythemia-vera
Manouche
in
MPN Voice
1 year ago
Clinical Trial Exceed ET
It is to determine the efficacy of using
Ropeginterferon
alfa
-
2b
-njft for the treatment of Essential Thrombocythemia. It has been approved for use in the treatment of PV, but not ET in the US, as I understand it.
It is to determine the efficacy of using
Ropeginterferon
alfa
-
2b
-njft for the treatment of Essential Thrombocythemia. It has been approved for use in the treatment of PV, but not ET in the US, as I understand it.
dogsandhorses
in
MPN Voice
5 months ago
Need your advice please
For the last 60 years I have been a vigilant weight watcher, daily exerciser and have watched my calorie intake. When I commenced treatment for my Essential Thrombocytosis in January 2021, my weight was 53.5kg. Three years later this has ballooned to 60.3kg, despite my efforts to control any
For the last 60 years I have been a vigilant weight watcher, daily exerciser and have watched my calorie intake. When I commenced treatment for my Essential Thrombocytosis in January 2021, my weight was 53.5kg. Three years later this has ballooned to 60.3kg, despite my efforts to control any
Goosebumps52
in
MPN Voice
3 months ago
Besremi trial for ET
https://www.businesswire.com/news/home/20230223005186/en/PharmaEssentia-Initiates-Phase-
2b
-Trial-of-
ropeginterferon
-
alfa
-
2b
-njft-for-Essential-Thrombocythemia-ET-in-North-America
https://www.businesswire.com/news/home/20230223005186/en/PharmaEssentia-Initiates-Phase-
2b
-Trial-of-
ropeginterferon
-
alfa
-
2b
-njft-for-Essential-Thrombocythemia-ET-in-North-America
wateron
in
MPN Voice
1 year ago
Besremi info
https://www.businesswire.com/news/home/20230202005200/en/Clinical-Review-of-
ropeginterferon
-
alfa
-
2b
-Suggests-Amended-Dosing-Schedule-May-Support-Improved-Clinical-Outcomes-in-Polycythemia-Vera
https://www.businesswire.com/news/home/20230202005200/en/Clinical-Review-of-
ropeginterferon
-
alfa
-
2b
-Suggests-Amended-Dosing-Schedule-May-Support-Improved-Clinical-Outcomes-in-Polycythemia-Vera
wateron
in
MPN Voice
1 year ago
Peginterferon alfa-2a
Hola! I'm new to this group and newly diagnosed with essential thrombocythemia. The treatment prescribed is peginterferon alfa-2a. So far I have done one treatment and wow does it suck! I haven't seen anyone else talking about this course of treatment. Is anyone else doing this? I sure could use some
Hola! I'm new to this group and newly diagnosed with essential thrombocythemia. The treatment prescribed is peginterferon alfa-2a. So far I have done one treatment and wow does it suck! I haven't seen anyone else talking about this course of treatment. Is anyone else doing this? I sure could use some
LisaLoveTacos
in
MPN Voice
5 months ago
Peginterferon alfa 2a or Hydroxycarbamide for PV?
My consultant has said I need to start treatment for PV and has asked me to choose between them. I'd really welcome any recommendations. I am new to this site, apologies uf this has been asked before.
My consultant has said I need to start treatment for PV and has asked me to choose between them. I'd really welcome any recommendations. I am new to this site, apologies uf this has been asked before.
Lyndjs
in
MPN Voice
7 months ago
Real world experience with Besremi in ET and PV following exposure to Pegasys.
Third generation pegylated IFNα,
ropeginterferon
alfa
-
2b
(ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV).
Third generation pegylated IFNα,
ropeginterferon
alfa
-
2b
(ropegIFN; Besremi), was recommended by the European Medicine Authority (EMA) for treatment of Polycythaemia Vera (PV) following a Phase III trial (PROUD-PV / CONTINUATION-PV).
Manouche
in
MPN Voice
1 year ago
New evidence on the early treatment of low-risk PV patients (using IFN)
alfa
-
2b
not only reduces the number of required phlebotomies but also brings additional significant benefit to the patient by better controlling the target hematocrit, stabilizing the disease and improving patients' quality of life."
alfa
-
2b
not only reduces the number of required phlebotomies but also brings additional significant benefit to the patient by better controlling the target hematocrit, stabilizing the disease and improving patients' quality of life."
Joey1025
in
MPN Voice
1 year ago
Besremi trial
My focus is in myeloid malignancies with a research focus in myeloproliferative neoplasms.Graphic: What is
ropeginterferon
?Dr. Mascarenhas: So,
Ropeginterferon
is a type of interferon
alfa
-
2b
.
My focus is in myeloid malignancies with a research focus in myeloproliferative neoplasms.Graphic: What is
ropeginterferon
?Dr. Mascarenhas: So,
Ropeginterferon
is a type of interferon
alfa
-
2b
.
wateron
in
MPN Voice
1 year ago
Interesting
Across the studies,
ropeginterferon
alfa
-
2b
was generally well-tolerated. No thromboembolic complications have been reported with the accelerated titration regimen in PV.
Across the studies,
ropeginterferon
alfa
-
2b
was generally well-tolerated. No thromboembolic complications have been reported with the accelerated titration regimen in PV.
wateron
in
MPN Voice
1 year ago
Besremi - NHS
can anyone confirm whether Besremi /
ropeginterferon
-
Alfa
-
2b
is approved for first line treatment of Polycythemia Vera on the NHS. im 41, diagnosed 5years ago, fit and healthy but obviously concerned about the long term progression risk.
can anyone confirm whether Besremi /
ropeginterferon
-
Alfa
-
2b
is approved for first line treatment of Polycythemia Vera on the NHS. im 41, diagnosed 5years ago, fit and healthy but obviously concerned about the long term progression risk.
Steve_Essex
in
MPN Voice
1 year ago
Besremi dosing research
[The response outcomes observed in multiple clinical trials of
ropeginterferon
alfa
-
2b
confirm clinical benefits in MPN patients. Emerging data utilizing the 250-350-500 mcg regimen suggest that a higher initial dose with faster dose titration may lead to earlier complete hematological remission.
[The response outcomes observed in multiple clinical trials of
ropeginterferon
alfa
-
2b
confirm clinical benefits in MPN patients. Emerging data utilizing the 250-350-500 mcg regimen suggest that a higher initial dose with faster dose titration may lead to earlier complete hematological remission.
Wennn
in
MPN Voice
1 year ago
Interferons as the First Choice of Cytoreduction in ET and PV
There has been a recent resurgence of interest in interferons for MPNs given the development of pegylated formulations, including pegylated interferon
alfa
-2a (Pegasys), pegylated interferon
alfa
-
2b
(PegIntron), and
ropeginterferon
alfa
-
2b
(Besremi).
There has been a recent resurgence of interest in interferons for MPNs given the development of pegylated formulations, including pegylated interferon
alfa
-2a (Pegasys), pegylated interferon
alfa
-
2b
(PegIntron), and
ropeginterferon
alfa
-
2b
(Besremi).
Manouche
in
MPN Voice
2 years ago
Besremi has (No?) Preservative
In the FDA label it says there isn't any: "BESREMi (
ropeginterferon
alfa
-
2b
-njft) injection is a sterile, preservative-free..." https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761166s000lbl.pdf -In the Euro label there is no mention of preservative at all.
In the FDA label it says there isn't any: "BESREMi (
ropeginterferon
alfa
-
2b
-njft) injection is a sterile, preservative-free..." https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761166s000lbl.pdf -In the Euro label there is no mention of preservative at all.
EPguy
in
MPN Voice
2 years ago
1
2
...
4
Next page
Filter results
Clear filters
Posted in
All communities
MPN Voice
55 results
HFI Connect - Hepatitis
2 results
Advanced Prostate Cancer
1 result
View top 10 communities
Sort by
Most Relevant
Newest